ES2188184T3 - Compuestos de beta-carbolinas. - Google Patents
Compuestos de beta-carbolinas.Info
- Publication number
- ES2188184T3 ES2188184T3 ES99928479T ES99928479T ES2188184T3 ES 2188184 T3 ES2188184 T3 ES 2188184T3 ES 99928479 T ES99928479 T ES 99928479T ES 99928479 T ES99928479 T ES 99928479T ES 2188184 T3 ES2188184 T3 ES 2188184T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- group
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Un compuesto de fórmula (I), **(Fórmula)** las mezclas racémico - diastereoméricas y los isómeros ópticos de dicho compuesto de fórmula (I), las sales o profármacos farmacéuticamente aceptables del mismo o una sal farmacéuticamente aceptable de dicho profármaco, en donde ------ representa un enlace opcional; X es N o N - R4, donde X es N cuando ambos enlaces opcionales están presentes y X es N - R4 cuando los enlaces opcionales no están presentes; R1 es: H, - (CH2)m - C(O) - (CH2)m - Z1, - (CH2)m - Z1, - (CH2)m - O - Z1 o alquil(C0 - C6) C(O) - NH - (CH2)m - Z3; Z1 es un resto opcionalmente sustituid escogido entre el grupo formado por: alquilo(C1 - C12), benzo[b]tiofeno, fenilo, naftilo, benzo[b]furanilo, tiofeno, isoxazolilo, indolilo, **(Fórmula)** R2 es: alquilo(C1 - C12), alquil(C0 - C5) - C(O) - O - Z5, alquil(C0 - C6) - C(O) - NH - (CH2)m - Z3 o fenilo opcionalmente sustituido; Z5 es: H, alquilo(C1 - C12) o (CH2)m - arilo; Z3 es: amino, alquil(C1 - C12)amino, N, N - di - alquil(C1 -C12)amino, - NH - C(O) - O - (CH2)m fenilo, - NH - C(O) - O - (CH2)m - alquilo(C1 - C6) o un resto opcionalmente sustituido escogido entre el grupo formado por: imidazolilo, piridinilo y morfolinilo, piperidinilo, piperacinilo, pirazolidinilo, furanilo y tiofeno R3 es: H; R4 es: H, - C(=Y) - N(X1X2), C(=O)X2 o X2; Y es: O o S; X2 es: - (CH2)m - Y1 - X3 0 X3 es: H o un resto opcionalmente sustituido escogido entre el grupo formado por: alquilo(C1 C12), cicloalquilo(C3 - C8), alcoxi(C1 - C12), ariloxi, alquil(C1 - C12) - amino, N, N - di - alquil(C1 C12) - amino, - CH - di - alcoxi(C1 - C12) o fenilo; R5 es: alquilo(C1 - C12), - (CH2), , , , - Y1 - (CH2), , , , - fenil - (X1), , , , cicloalquilo(C3 - C12), - (CH2), , , , S - alquilo(C1 - C12), alquil(C1 - C12) - S - S - alquilo(C1 - C12), - (CH2)m - alquenilo(C1 - C12) o un resto opcionalmente sustituido escogido entre el grupo formado por: fenilo, furanilo, tiofeno, pirrolilo, piridinilo y **Fórmula** Y1 es: O, S, NH o un enlace; R6 es H o SO2 - fenilo; R7 es H, alquilo opcionalmente sustituido con alcoxi o dialquilamino; en donde un resto opcionalmente sustituido un fenilo opcionalmente sustituido, se sustituye opcionalmente por uno o más sustituyentes, cada uno escogido independientemente entre el grupo formado por: Cl, F, Br, I, CF3, NO2, OH, SO2NH2, CN, N3, - OCF3, alcoxi(C1 - C12), - (CH2), , , , - fenil - (X1), , , , - NH - CO - alquilo(C1 - C6), - S - fenil - (X1), , , , O - (CH2), , , . - fenil - (X1), , , , - (CH2), , , . - C(O) O - alquilo(C1 - C6), - (CH2), , , , , - C(O) - alquilo(C1 - C6), - O - (CH), , , , , - NH - alquilo(C1 - C6), - O - (CH2)-, , , , - N - di - (alquilo(C1 - C6)) y alquil(C0 - C12) - (X1)n; X1, cada vez que aparezca se escoge independientemente entre el grupo formado por: hidrógeno, Cl, F, Br, I, NO2, OH, - CF3, - OCF3 - , alquilo(C1 - C12), alcoxi(C1 - C12), - S - alquilo(C1 - C6), - (CH2)-, , , , - amino, - (CH2)-, , , , - NH - alquilo(C1 - C6), - (CH2)-, , , , - N - di - (alquilo(C1 - C6)),- (CH2)-, , , , fenilo y, - (CH2)-, , , , - NH - cicloalquilo(C3 - C6); m, cada vez que aparezca, es independientemente 0 ¿ o un número entero entre 1 y 6; y n, cada vez que aparezca, es independientemente un número entero entre 1 y 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9729798A | 1998-06-12 | 1998-06-12 | |
US8918098P | 1998-06-12 | 1998-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2188184T3 true ES2188184T3 (es) | 2003-06-16 |
Family
ID=26780327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99928479T Expired - Lifetime ES2188184T3 (es) | 1998-06-12 | 1999-06-08 | Compuestos de beta-carbolinas. |
Country Status (22)
Country | Link |
---|---|
US (1) | US6586445B1 (es) |
EP (1) | EP1086101B1 (es) |
JP (1) | JP2002517500A (es) |
KR (1) | KR20010071461A (es) |
CN (1) | CN1169808C (es) |
AR (1) | AR019153A1 (es) |
AT (1) | ATE229954T1 (es) |
AU (1) | AU761020B2 (es) |
CA (1) | CA2335339A1 (es) |
CZ (1) | CZ20004580A3 (es) |
DE (1) | DE69904595T2 (es) |
DK (1) | DK1086101T3 (es) |
ES (1) | ES2188184T3 (es) |
HK (1) | HK1032049A1 (es) |
HU (1) | HUP0302962A2 (es) |
IL (1) | IL140197A0 (es) |
NO (1) | NO319532B1 (es) |
NZ (1) | NZ508765A (es) |
PL (1) | PL345589A1 (es) |
RU (1) | RU2233841C2 (es) |
TW (1) | TWI236477B (es) |
WO (1) | WO1999064420A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
US6696418B1 (en) | 1999-09-01 | 2004-02-24 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
FR2812546B1 (fr) * | 2000-08-01 | 2008-11-21 | Sod Conseils Rech Applic | Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments |
TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
US6495589B2 (en) | 2000-04-28 | 2002-12-17 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
US6720330B2 (en) | 2000-11-17 | 2004-04-13 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
FR2818978B1 (fr) * | 2000-12-28 | 2003-02-28 | Sod Conseils Rech Applic | Modulateurs de canaux sodiques derives de 2-piperidylimidazoles |
GB0108337D0 (en) | 2001-04-03 | 2001-05-23 | Novartis Ag | Organic compounds |
TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
CZ20033123A3 (cs) * | 2001-06-25 | 2004-11-10 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farmaceutické prostředky, které inhibují proliferaci adenomů hypofýzy |
DE10136842A1 (de) * | 2001-07-23 | 2003-02-13 | Schering Ag | GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität |
US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
PA8586801A1 (es) | 2002-10-31 | 2005-02-04 | Pfizer | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
BRPI0407052A (pt) | 2003-01-27 | 2006-01-17 | Pfizer | Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
CN101837127A (zh) | 2003-05-05 | 2010-09-22 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
WO2004113300A1 (ja) | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 新規三環性複素環化合物 |
WO2005039548A2 (en) | 2003-10-15 | 2005-05-06 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
ATE541835T1 (de) * | 2004-02-05 | 2012-02-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
JP2007534738A (ja) | 2004-04-26 | 2007-11-29 | ファイザー・インク | Hivインテグラーゼ酵素の阻害剤 |
WO2005103003A2 (en) | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
DE102004039382A1 (de) | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
EP1829874B1 (en) | 2004-12-22 | 2014-02-12 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
WO2006089053A2 (en) | 2005-02-17 | 2006-08-24 | Wyeth | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
JP5035865B2 (ja) * | 2005-09-26 | 2012-09-26 | 国立大学法人高知大学 | Helicobacterpylori菌株の増殖・運動抑制方法 |
WO2007062175A2 (en) * | 2005-11-21 | 2007-05-31 | Amgen Inc. | Spiro-substituted tricyclic heterocycles cxcr3 antagonists |
US7879859B2 (en) * | 2005-11-21 | 2011-02-01 | Merck Sharp & Dohme Corp. | Diagnosis and treatment of type 2 diabetes and other disorders |
CN101346375B (zh) * | 2005-11-23 | 2013-04-10 | 阿罗斯药物有限责任公司 | 调节门离子通道用组合物和方法 |
US20080004306A1 (en) * | 2006-04-10 | 2008-01-03 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
CA2693214A1 (en) * | 2007-07-19 | 2009-01-22 | Merck Sharp & Dohme Corp. | Beta carboline derivatives as antidiabetic compounds |
SG10201703086VA (en) * | 2008-10-17 | 2017-05-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
WO2010051177A1 (en) * | 2008-10-29 | 2010-05-06 | Merck Sharp & Dohme Corp. | Triazole beta carboline derivatives as antidiabetic compounds |
TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
CN102844029A (zh) * | 2009-12-28 | 2012-12-26 | 奥迪欧医药设备有限公司 | 用于治疗听力损伤和眩晕的β-咔啉 |
CN102695414A (zh) | 2010-01-15 | 2012-09-26 | 默沙东公司 | 作为抗糖尿病化合物的噁二唑β-咔啉衍生物 |
KR101256588B1 (ko) * | 2010-02-17 | 2013-04-19 | 부산대학교 산학협력단 | 베타-카르볼린 알칼로이드를 함유하는 멜라닌 생성 촉진용 조성물 |
KR101784284B1 (ko) * | 2011-03-28 | 2017-10-11 | 에스제이티 몰레큘라 리서치, 에스.엘. | 대사증후군 치료 화합물 |
CN105837569B (zh) * | 2016-04-29 | 2017-12-26 | 华南农业大学 | 一种骆驼蓬碱噁唑啉类化合物及其制备方法和应用 |
CN107118212B (zh) * | 2017-05-26 | 2019-12-03 | 广西师范大学 | 1-吡啶-6-甲氧基-9-(3-碘苄)-β-咔啉、合成和应用 |
CN107163041B (zh) * | 2017-05-26 | 2019-06-21 | 广西师范大学 | 一种β-咔啉化合物及其合成方法和应用 |
CN106995440B (zh) * | 2017-05-26 | 2019-09-03 | 广西师范大学 | 1-吡啶-6-甲氧基-9-(2,3,4,5-四氟苄基)β-咔啉化合物及其合成方法和应用 |
CN107141285B (zh) * | 2017-05-26 | 2019-12-03 | 广西师范大学 | 1-吡啶-6-甲氧基-9-甲基苄-β-咔啉及其合成和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378803A (en) * | 1987-12-11 | 1995-01-03 | Sterling Winthrop Inc. | Azole-fused peptides and processes for preparation thereof |
-
1999
- 1999-06-08 AT AT99928479T patent/ATE229954T1/de not_active IP Right Cessation
- 1999-06-08 US US09/719,455 patent/US6586445B1/en not_active Expired - Lifetime
- 1999-06-08 DK DK99928479T patent/DK1086101T3/da active
- 1999-06-08 KR KR1020007014116A patent/KR20010071461A/ko not_active Application Discontinuation
- 1999-06-08 HU HU0302962A patent/HUP0302962A2/hu unknown
- 1999-06-08 CN CNB998081612A patent/CN1169808C/zh not_active Expired - Fee Related
- 1999-06-08 ES ES99928479T patent/ES2188184T3/es not_active Expired - Lifetime
- 1999-06-08 NZ NZ508765A patent/NZ508765A/en unknown
- 1999-06-08 PL PL99345589A patent/PL345589A1/xx not_active Application Discontinuation
- 1999-06-08 CA CA002335339A patent/CA2335339A1/en not_active Abandoned
- 1999-06-08 JP JP2000553429A patent/JP2002517500A/ja active Pending
- 1999-06-08 RU RU2001101433/04A patent/RU2233841C2/ru not_active IP Right Cessation
- 1999-06-08 EP EP99928479A patent/EP1086101B1/en not_active Expired - Lifetime
- 1999-06-08 DE DE69904595T patent/DE69904595T2/de not_active Expired - Fee Related
- 1999-06-08 IL IL14019799A patent/IL140197A0/xx unknown
- 1999-06-08 WO PCT/US1999/012874 patent/WO1999064420A1/en not_active Application Discontinuation
- 1999-06-08 CZ CZ20004580A patent/CZ20004580A3/cs unknown
- 1999-06-08 AU AU45536/99A patent/AU761020B2/en not_active Ceased
- 1999-06-11 AR ARP990102812A patent/AR019153A1/es not_active Application Discontinuation
- 1999-08-11 TW TW088109827A patent/TWI236477B/zh not_active IP Right Cessation
-
2000
- 2000-12-11 NO NO20006268A patent/NO319532B1/no unknown
-
2001
- 2001-04-04 HK HK01102432A patent/HK1032049A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2233841C2 (ru) | 2004-08-10 |
IL140197A0 (en) | 2002-02-10 |
DE69904595D1 (de) | 2003-01-30 |
CN1169808C (zh) | 2004-10-06 |
DK1086101T3 (da) | 2003-03-31 |
AR019153A1 (es) | 2001-12-26 |
CA2335339A1 (en) | 1999-12-16 |
ATE229954T1 (de) | 2003-01-15 |
NO20006268D0 (no) | 2000-12-11 |
DE69904595T2 (de) | 2003-11-27 |
US6586445B1 (en) | 2003-07-01 |
EP1086101B1 (en) | 2002-12-18 |
WO1999064420A1 (en) | 1999-12-16 |
PL345589A1 (en) | 2001-12-17 |
JP2002517500A (ja) | 2002-06-18 |
HK1032049A1 (en) | 2001-07-06 |
NZ508765A (en) | 2003-10-31 |
AU4553699A (en) | 1999-12-30 |
AU761020B2 (en) | 2003-05-29 |
EP1086101A1 (en) | 2001-03-28 |
NO319532B1 (no) | 2005-08-29 |
NO20006268L (no) | 2001-01-29 |
CZ20004580A3 (cs) | 2001-12-12 |
HUP0302962A2 (hu) | 2003-12-29 |
CN1308632A (zh) | 2001-08-15 |
TWI236477B (en) | 2005-07-21 |
KR20010071461A (ko) | 2001-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2188184T3 (es) | Compuestos de beta-carbolinas. | |
CY1107388T1 (el) | Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων | |
NO20022317D0 (no) | Trifenylalkylen-derivater og deres anvendelse som selektive östrogen-reseptor-modulater | |
ES2189462T3 (es) | Derivados de acido aminometilcarboxilico. | |
CO5611126A2 (es) | Derivados de indolinona utiles como inhibidores de la proteina cinasa | |
ES2196772T3 (es) | Compuestos amino ciclicos. | |
CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
TW336932B (en) | Amino-substituted pyrazoles | |
HUP0301607A2 (hu) | Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR012032A1 (es) | Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion | |
DK1260512T3 (da) | Hidtil ukendte, cykliske amidderivater | |
AR001787A1 (es) | Un compuesto oxazolidin sustituido particularmenteutil como inhibidor de calpaina y/o catepsina b e n el tratamiento de trastornos neurodegenerativos agudos o cronicos y composiciones farmacéuticas que incluyen dicho compuesto | |
CO5271680A1 (es) | Compuestos | |
HRP20100283T8 (en) | Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
AR026505A1 (es) | Proceso mejorado para la preparacion de aminotetralinas sustituidas con nitrogeno | |
HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
TW328089B (en) | New azolidinediones as antihyperglycemic agents | |
CO5031246A1 (es) | Compuestos calciliticos | |
PE20001063A1 (es) | Nuevos agentes antibacterianos de isoxazolinona | |
EA200300927A1 (ru) | Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов | |
CO5021223A1 (es) | Compuestos calciliticos calciliticos | |
CO4990972A1 (es) | Derivados de eritromicina en puente 6,11 | |
DK0677042T3 (da) | Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler | |
AR054414A1 (es) | Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas. | |
RS50289B (sr) | Novi razgranati supstituisani amino derivati od 3-amino-1- fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže |